The PCSK9 inhibitor lowered LDL cholesterol by 38% vs placebo in HAUSER-RCT, the first randomized controlled trial of one of these agents in the pediatric population.
Medscape Medical News
Healthy life is yours
Healthy life is yours
The PCSK9 inhibitor lowered LDL cholesterol by 38% vs placebo in HAUSER-RCT, the first randomized controlled trial of one of these agents in the pediatric population.
Medscape Medical News
More Stories
RCN row continues as petitioners complain of being shut out
Children and COVID-19: New Cases May Be Leveling Off
Women with prolonged fertility have elevated dementia risk